ArticleBMC infectious diseases2025
Tracheobronchial infectious diseases in adult-onset immunodeficiency with anti-interferon-gamma autoantibodies.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative measurement of anti-interferon-gamma autoantibodies for routine laboratory implementation.iScience · 2026Article
- Tracheobronchial invasion by nontuberculous mycobacteria: a rare but overlooked clinical manifestation-a multicenter retrospective analysis.Frontiers in cellular and infection microbiology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAnti-interferon (IFN)-γ autoantibodies predispose subjects to infections caused by opportunistic intracellular pathogens and lead to the involvement of multiple well-recognized organs, such as the lungs, skin, and lymph nodes. However, the clinical characteristics of tracheobronchial involvement remain unrecognized.
methodsA retrospective study was conducted between February 2016 and September 2024, enrolling patients with anti-IFN-γ autoantibodies who had documented evidence of tracheobronchial involvement. The clinical data were analyzed, including demographic information, clinical manifestations, laboratory results, chest computed tomography images, bronchoscopy findings, treatments, and clinical outcomes.
resultsA total of 33 patients were enrolled, with a mean age of 51.73 years old. The top five reported symptoms were cough, expectoration, fever, dyspnea, and fatigue. Laboratory tests showed elevated white blood cells, C-reactive protein, erythrocyte sedimentation rate, globulin, and immunoglobulin G. The detected pathogens included commonly reported opportunistic pathogens, such as Talaromyces marneffei (57.58%) and nontuberculous mycobacteria (42.42%), as well as the conventional pathogens typically found in patients without immunodeficiency diseases. Masses, nodules, and tracheobronchial stenosis were commonly seen on chest computed tomography scans and during bronchoscopy, directly indicating airway involvement. The predominant pathological results of the tracheobronchial lesions were chronic inflammation, with a small subset showing granuloma formation and abscess formation. Twenty-six patients (78.79%) achieved clinical improvement. Adverse events related to the therapeutic drug were reported in 30.3% of patients, with no life-threatening events.
conclusionsTracheobronchial lesions are characterized by masses, nodules, and tracheobronchial stenosis visualized during bronchoscopy, as well as inflammatory changes confirmed by pathologic examinations. Clinicians should be vigilant for tracheobronchial infections, particularly those caused by Talaromyces marneffei and nontuberculous mycobacteria. Pathogen-targeted therapy shows therapeutic benefits but requires close monitoring for drug-related toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.